The Australian Pharmaceutical Industries Ltd (ASX: API) share price has fallen over 6% to $1.41 after the release of its half-yearly for the period ended 28 February 2018 yesterday. The stock has now lost 31% over the last 12 months as the company faces…
To keep reading, enter your email address or login below.
The Australian Pharmaceutical Industries Ltd (ASX: API) share price has fallen over 6% to $1.41 after the release of its half-yearly for the period ended 28 February 2018 yesterday.
The stock has now lost 31% over the last 12 months as the company faces an increasingly difficult operating environment in its Priceline retail stores network and pharmacy distribution business.
Flat revenue and declining profitability
Revenue for the group was essentially flat, dropping 0.3% to $2.0 billion for the period. Retail register sales from Priceline fell by 0.3% to $593 million despite the number of network stores increasing to 466 from 450 in the prior corresponding period.
This resulted in comparable store sales shrinking by 1.7% as the company’s retail arm struggles with a subdued Australian consumer battling low wages growth and high utility bills.
Pharmacy distribution revenue was 0.3% lower to $1.45 billion and was negatively impacted by reduced demand for high cost Hepatitis C medicines as also seen in rival Sigma Healthcare Limited (ASX: SIG).
Eliminating the impact from the Hepatitis C reduction and Pharmaceutical Benefits Scheme (PBS) reforms resulted in underlying sales growth being 9.8% higher than the prior period, underpinned by gains from independent pharmacies.
After backing out a $2.6 million adjustment related to business restructuring and strategic business growth, underlying net profit after tax for the group fell 8.1% to $26.8 million with underlying earnings per share decreasing 10% to 5.4 cents. Management expects the company’s FY18 underlying result to be marginally above its FY17 result under the assumption that current trading conditions do not worsen.
This was a result roughly in line with the expectations management outlined at the company’s AGM in January. Given the current issues in the Australian retail and pharmacy distribution segments it is difficult to build a compelling bullish thesis for the company in the near term. The company’s largest shareholder, Washington H. Soul Pattinson and Co. Ltd (ASX: SOL), notably decreased its ownership interest in the business last year.
However, one thing to watch out for is the possibility of Australian Pharmaceutical Industries taking over Sigma Healthcare’s wholesale supply contract for the My Chemist/Chemist Warehouse Group which ends in June 2019 and is up for tender.
It's been a nail-biter of a reporting season here in the first half of 2018.
But the real action, in my opinion, is what companies are doing with dividends.
What does this mean for you? Well there is one stock I've found that could very well turn out to be THE best buy of 2018. And while there's no such thing as a 'sure thing' when it comes to investing - this ripper might come as close as I've ever seen.
Motley Fool contributor Tim Katavic has no financial interest in any company mentioned. The Motley Fool Australia owns shares of and has recommended Washington H. Soul Pattinson and Company Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.